ArticleJournal of market access & health policy2018

Establishing the cost of implementing a performance-based, managed entry agreement for a hypothetical CAR T-cell therapy.

Panos Kefalas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.